You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHydrocodone
Accession NumberDB00956  (APRD00591)
TypeSmall Molecule
GroupsApproved, Illicit
Description

Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
(-)-DihydrocodeinoneNot AvailableNot Available
4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-oneNot AvailableNot Available
DihydrocodeinoneNot AvailableNot Available
HidrocodonaSpanishINN
HydrocodonNot AvailableNot Available
HydrocodoneNot AvailableNot Available
HydrocodonumLatinINN
HydroconeNot AvailableNot Available
HydroconumNot AvailableNot Available
IdrocodoneNot AvailableDCIT
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Zohydrocapsule, extended release10 mgoralZogenix, Inc.2013-10-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release15 mgoralZogenix, Inc.2013-10-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release20 mgoralZogenix, Inc.2013-10-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release30 mgoralZogenix, Inc.2013-10-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release40 mgoralZogenix, Inc.2013-10-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release50 mgoralZogenix, Inc.2013-10-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Reprexaintablet10; 200 mg/1; mgoralStat Rx USA2008-12-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Reprexaintablet, film coated5; 200 mg/1; mgoralStat Rx USA2008-12-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Reprexaintablet, film coated2.5; 200 mg/1; mgoralQuinnova Pharmaceuticals, LLC2010-02-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Reprexaintablet, film coated5; 200 mg/1; mgoralQuinnova Pharmaceuticals, LLC2010-02-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Reprexaintablet, film coated10; 200 mg/1; mgoralQuinnova Pharmaceuticals, LLC2010-02-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Reprexaintablet, film coated2.5; 200 mg/1; mgoralGemini Laboratories, LLC2013-12-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Reprexaintablet, film coated5; 200 mg/1; mgoralGemini Laboratories, LLC2013-12-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Reprexaintablet, film coated10; 200 mg/1; mgoralGemini Laboratories, LLC2013-12-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixtures
Brand NameIngredients
Caldomine DHHydrocodone Bitartrate + Pheniramine Maleate + Phenylpropanolamine Hydrochloride + Pyrilamine Maleate
Coristine-DHHydrocodone Bitartrate + Phenylephrine Hydrochloride
DalmacolAlcohol Anhydrous + Doxylamine Succinate + Etafedrin Hydrochloride + Hydrocodone Bitartrate + Sodium Citrate
Dimetane Expectorant-DCBrompheniramine Maleate + Guaifenesin + Hydrocodone Bitartrate + Phenylephrine Hydrochloride + Phenylpropanolamine Hydrochloride
HycetAcetaminophen + Hydrocodone
Hycomine-SAmmonium Chloride + Hydrocodone Bitartrate + Phenylephrine Hydrochloride + Pyrilamine Maleate
IBUDONEHydrocodone + Ibuprofen
MaxidoneAcetaminophen + Hydrocodone
Mercodol with DecaprynDoxylamine Succinate + Etafedrin Hydrochloride + Hydrocodone Bitartrate + Sodium Citrate
NORCOHydrocodone + Ibuprofen
Novahistex DGGuaifenesin + Hydrocodone Bitartrate + Phenylephrine Hydrochloride
Novahistex DHHydrocodone Bitartrate + Phenylephrine Hydrochloride
Ratio-CalmydoneDoxylamine Succinate + Etafedrin Hydrochloride + Hydrocodone Bitartrate + Sodium Citrate
Ratio-Coristex-DHHydrocodone Bitartrate + Phenylephrine Hydrochloride
REPREXAINHydrocodone + Ibuprofen
REZIRAHydrocodone + Ibuprofen
Solucodan SyrupHydrocodone Bitartrate + Menthol + Potassium Guaiacol Sulphonate + Sodium Citrate
Solucodan-HDiphenylpyraline Hydrochloride + Hydrocodone Bitartrate + Menthol + Potassium Guaiacol Sulphonate + Sodium Citrate
Triaminic Expectorant DH SyrupGuaifenesin + Hydrocodone Bitartrate + Pheniramine Maleate + Phenylpropanolamine Hydrochloride + Pyrilamine Maleate
Tussaminic DHHydrocodone Bitartrate + Pheniramine Maleate + Phenylpropanolamine Hydrochloride + Pyrilamine Maleate
TUSSICAPSHydrocodone + Ibuprofen
VituzHydrocodone + Chlorphenamine
XodolAcetaminophen + Hydrocodone
ZAMICETAcetaminophen + Hydrocodone
ZolvitAcetaminophen + Hydrocodone
ZUTRIPROPseudoephedrine + Hydrocodone + Chlorphenamine
SaltsNot Available
Categories
CAS number125-29-1
WeightAverage: 299.3642
Monoisotopic: 299.152143543
Chemical FormulaC18H21NO3
InChI KeyLLPOLZWFYMWNKH-CMKMFDCUSA-N
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Isoquinolone
  • Tetralin
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor relief of moderate to moderately severe pain. Also used for the symptomatic relief of nonproductive cough, alone or in combination with other antitussives or expectorants.
PharmacodynamicsHydrocodone, a semisynthetic opiate agonist and hydrogenated ketone derivative, is similar to other phenanthrene derivatives, such as codeine. Used as an analgesic, hydrocodone is combined with acetaminophen, ibuprofen, or aspirin to treat pain. Used as an antitussive, hydrocodone is combined with phenylephrine, pseudoephedrine, phenylpropanolamine, guaifenesin, pyrilamine, pheniramine, or chlorpheniramine. Opiate agonists exert their principal pharmacologic effect at specific receptor binding sites in the CNS and other tissues. There are several subtypes of opiate receptors including the mu receptor (localized in pain modulating regions of the CNS), the kappa receptor (localized in the deep layers of the cerebral cortex), the delta receptor (localized in the limbic regions of the CNS), and the sigma receptor (thought to mediate the dysphoric and psychotomimetic effects of some opiate partial agonists). Agonist activity at the mu or kappa receptor can result in analgesia, miosis, and/or decreased body temperature. Agonist activity at the mu receptor can also result in suppression of opiate withdrawal, whereas antagonist activity can result in precipitation of withdrawal. Opiate agonists act at several sites within the CNS involving several systems of neurotransmitters to produce analgesia, but the precise mechanism of action has not been fully determined. Opiate agonists do not alter the threshold or responsiveness of afferent nerve endings to noxious stimuli nor the conduction of impulses along peripheral nerves. Instead, they alter the perception of pain at the spinal cord and higher levels in the CNS and the person's emotional response to pain.
Mechanism of actionHydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Hydrocodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as hydrocodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
AbsorptionWell absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingAs most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% [hydromorphone] to 45% [oxycodone]), hydrocodone is expected to fall within this range.
Metabolism

Hepatic and also in intestinal mucosa.

SubstrateEnzymesProduct
Hydrocodone
hydromorphoneDetails
Hydrocodone
norhydrocodoneDetails
Route of eliminationNot Available
Half life1.25-3 hours
ClearanceNot Available
ToxicitySymptoms of overdose include respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur. LD50=85.7mg/kg (subcutaneous, in mice).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9984
Caco-2 permeable+0.8621
P-glycoprotein substrateSubstrate0.8253
P-glycoprotein inhibitor IInhibitor0.6425
P-glycoprotein inhibitor IINon-inhibitor0.8664
Renal organic cation transporterInhibitor0.6604
CYP450 2C9 substrateNon-substrate0.8546
CYP450 2D6 substrateSubstrate0.8997
CYP450 3A4 substrateSubstrate0.8168
CYP450 1A2 substrateNon-inhibitor0.8207
CYP450 2C9 substrateNon-inhibitor0.9412
CYP450 2D6 substrateInhibitor0.6629
CYP450 2C19 substrateNon-inhibitor0.8402
CYP450 3A4 substrateNon-inhibitor0.7625
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8675
Ames testNon AMES toxic0.7735
CarcinogenicityNon-carcinogens0.9419
BiodegradationNot ready biodegradable0.984
Rat acute toxicity3.0914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9024
hERG inhibition (predictor II)Non-inhibitor0.8165
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral10 mg
Capsule, extended releaseoral15 mg
Capsule, extended releaseoral20 mg
Capsule, extended releaseoral30 mg
Capsule, extended releaseoral40 mg
Capsule, extended releaseoral50 mg
Tabletoral10; 200 mg/1; mg
Tablet, film coatedoral10; 200 mg/1; mg
Tablet, film coatedoral2.5; 200 mg/1; mg
Tablet, film coatedoral5; 200 mg/1; mg
Prices
Unit descriptionCostUnit
Hydrocodone-Acetaminophen 7.5-500 mg/15ml Solution 473ml Bottle60.97USD bottle
Hydrocodone-Ibuprofen 7.5-200 mg tablet1.13USD tablet
Hydrocodone-Acetaminophen 10-750 mg tablet1.1USD tablet
Hydrocodone-Acetaminophen 7.5-325 mg tablet0.63USD tablet
Hydrocodone-Acetaminophen 10-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 5-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 10-660 mg tablet0.53USD tablet
Hydrocodone-Acetaminophen 10-500 mg tablet0.5USD tablet
Hydrocodone-Acetaminophen 10-650 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 7.5-500 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 2.5-500 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 7.5-750 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 5-500 mg tablet0.4USD tablet
Hydrocodone-Acetaminophen 7.5-650 mg tablet0.16USD tablet
Hydrocodone-Homatropine 5-1.5 mg/5ml Syrup0.15USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point198 °CPhysProp
water solubilityInsolubleNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.797 mg/mLALOGPS
logP2.13ALOGPS
logP1.96ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)18ChemAxon
pKa (Strongest Basic)8.61ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.74 m3·mol-1ChemAxon
Polarizability32.05 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.3 KB)
SpectraMS
References
Synthesis Reference

Anne M. Hailes, Christopher E. French, Neil C. Bruce, “Morphinone reductase for the preparation of hydromorphone and hydrocodone.” U.S. Patent US5571685, issued November, 1990.

US5571685
General ReferenceNot Available
External Links
ATC CodesR05DA03
AHFS Codes
  • 48:08.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (48.8 KB)
Interactions
Drug Interactions
Drug
AbirateroneCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
AcetaminophenCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
AcetazolamideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
AlfentanilCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
AlprazolamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
AlvimopanAnalgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.
AmilorideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
AmiodaroneCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
AmitriptylineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
AmlodipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
Ammonium chlorideMay increase the excretion of Analgesics (Opioid).
AmobarbitalCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
AmoxapineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
AmphetamineMay enhance the analgesic effect of Analgesics (Opioid).
AnastrozoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
ApomorphineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
AprepitantCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
AripiprazoleCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
armodafinilCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
ArtemetherCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
AsenapineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
AtazanavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
AtomoxetineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
AtorvastatinCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
BaclofenCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
BendroflumethiazideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
BicalutamideCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
BiotinCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
BoceprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
BortezomibCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
BosentanCYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocodone.
BrimonidineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
BromazepamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
BromocriptineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
BrompheniramineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
BumetanideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
BupropionCYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Hydrocodone. Specifically, concentrations of hydromorphone may be decreased.
BuspironeCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ButabarbitalCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ButalbitalCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
CalcitriolCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
CanagliflozinCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
CarbamazepineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
CarbinoxamineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
CarfilzomibCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
CarisoprodolCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
CathinoneMay enhance the analgesic effect of Analgesics (Opioid).
CetirizineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ChlordiazepoxideCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ChlorothiazideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
ChlorphenamineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ChlorpromazineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ChlorthalidoneAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
ChlorzoxazoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
CimetidineCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
CinacalcetCYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Hydrocodone. Specifically, concentrations of hydromorphone may be decreased.
CisaprideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
ClarithromycinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
ClemastineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ClidiniumCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ClobazamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ClomipramineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ClonazepamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ClonidineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ClotrimazoleCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
ClozapineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
CocaineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
CodeineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ConivaptanMay increase the serum concentration of CYP3A4 Substrates.
CrizotinibCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
CrofelemerCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
CyclizineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
CyclobenzaprineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
CyclophosphamideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
CyclothiazideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
CyproheptadineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
Cyproterone acetateCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DalfopristinCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
DanazolCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
DantroleneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DarifenacinCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
DarunavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
DasatinibMay increase the serum concentration of CYP3A4 Substrates.
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DelavirdineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
DesfluraneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DesipramineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DesloratadineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DesmopressinAnalgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.
DesogestrelCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
DesvenlafaxineCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
DexbrompheniramineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DiazepamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DicloxacillinCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
DifenoxinCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DihydrocodeineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DihydroergotamineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
DiltiazemCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
DimenhydrinateCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DiphenoxylateCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DisulfiramCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
DocetaxelCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
DoxycyclineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
DoxylamineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DronabinolMay enhance the CNS depressant effect of CNS Depressants.
DronedaroneCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
DroperidolCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
DrospirenoneCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
EliglustatCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
EnfluraneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
EntacaponeCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
EnzalutamideCYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocodone.
ErgotamineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
EribulinCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
EstazolamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
EszopicloneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
Ethacrynic acidAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
EthanolAlcohol (Ethyl) may enhance the CNS depressant effect of Hydrocodone. Alcohol (Ethyl) may increase the serum concentration of Hydrocodone.
Ethinyl EstradiolCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
EthosuximideCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
EthotoinCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
EthoxzolamideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
EthynodiolCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
EtoposideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
EtravirineCYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocodone.
ExemestaneCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
EzogabineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
FelbamateCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
FelodipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
FentanylCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
FexofenadineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
FluconazoleCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
FlunarizineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
FluoxetineCYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Hydrocodone. Specifically, concentrations of hydromorphone may be decreased.
FlupentixolCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
FlurazepamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
FluvastatinCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
FluvoxamineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
FosamprenavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
FosaprepitantMay increase the serum concentration of CYP3A4 Substrates.
FosphenytoinCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
FurosemideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
GabapentinCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
gabapentin enacarbilCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
Gamma Hydroxybutyric AcidCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
GlyburideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
Glycerol PhenylbutyrateCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
GriseofulvinCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
GuanfacineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
HaloperidolCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
HydralazineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
HydrochlorothiazideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
HydroflumethiazideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
HydromorphoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
HydroxyzineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
IfosfamideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
IloperidoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ImipramineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
IndapamideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
IndinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
IrbesartanCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
IsavuconazoniumCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
IsocarboxazidMAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.
IsofluraneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
IsomethepteneCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
IsoniazidCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
IsradipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
ItraconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
IvacaftorMay increase the serum concentration of CYP3A4 Substrates.
KetamineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
KetotifenCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
LamotrigineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
LansoprazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
LapatinibCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
LevetiracetamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
LevocabastineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
LevocetirizineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
LevorphanolCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
LinezolidMAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.
LomitapideCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
LomustineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
LopinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
LoratadineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
LorazepamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
LosartanCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
LovastatinCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
LoxapineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
LULICONAZOLEMay increase the serum concentration of CYP3A4 Substrates.
LumefantrineCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
LurasidoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
Magnesium SulfateMay enhance the CNS depressant effect of CNS Depressants.
MaprotilineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
MeclizineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
Medroxyprogesterone AcetateCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
MefloquineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
MeprobamateCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
MestranolCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
MethadoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
MethimazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
MethocarbamolCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
MethohexitalCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
MethotrimeprazineCNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.
MethsuximideCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
MethylprednisoloneCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
MetolazoneAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
MetyraponeCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
MetyrosineCNS Depressants may enhance the sedative effect of Metyrosine.
MicafunginCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
MidazolamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
MifepristoneMay increase the serum concentration of CYP3A4 Substrates.
MirabegronCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
MirtazapineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
MitoxantroneCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
MoclobemideMAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.
ModafinilCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
MorphineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
NabiloneMay enhance the CNS depressant effect of CNS Depressants.
NafcillinCYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocodone.
NaltrexoneMay diminish the therapeutic effect of Analgesics (Opioid).
NefazodoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
NelfinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
NevirapineCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
NifedipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
NilotinibCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
NisoldipineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
NitrazepamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
Nitrous oxideCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
NizatidineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
NorelgestrominCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
NorfloxacinCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
NorgestimateCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
NortriptylineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
OlanzapineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
OlopatadineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
OmeprazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
OritavancinCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
OrphenadrineCNS Depressants may enhance the CNS depressant effect of Orphenadrine.
OspemifeneCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
OxazepamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
OxcarbazepineCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
OxybutyninCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
OxycodoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
OxymorphoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PaliperidoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ParoxetineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
PazopanibCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
PegvisomantAnalgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.
PentamidineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
PentobarbitalCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PerampanelMay enhance the CNS depressant effect of CNS Depressants.
PerphenazineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PethidineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PhenelzineMAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.
PhenobarbitalCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PhenytoinCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PilocarpineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
PimozideCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PioglitazoneCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
PipotiazineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PizotifenCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PomalidomideCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PosaconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
PramipexoleCNS Depressants may enhance the sedative effect of Pramipexole.
PravastatinCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
PrednisoneCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
PregabalinCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PrimaquineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
PrimidoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ProcarbazineMAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.
ProchlorperazineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ProgesteroneCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
PromazineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PromethazineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
PropofolCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ProtriptylineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
QuazepamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
QuetiapineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
QuinidineQuiNIDine may decrease serum concentrations of the active metabolite(s) of Hydrocodone.
QuinineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
QuinupristinCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
RabeprazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
RamelteonCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
RanolazineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
RasagilineMAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.
RemifentanilCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ReserpineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
RifampicinCYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocodone.
RifapentineCYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocodone.
RisperidoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
RitonavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
RopiniroleCNS Depressants may enhance the sedative effect of ROPINIRole.
RotigotineCNS Depressants may enhance the sedative effect of Rotigotine.
RufinamideMay enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
SaquinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
ScopolamineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
SecobarbitalCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
SelegilineMAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.
SertralineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
SevofluraneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
SildenafilCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SimeprevirMay increase the serum concentration of CYP3A4 Substrates.
SirolimusCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
Sodium phenylbutyrateCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
SpironolactoneAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
SuccinylcholineMay enhance the bradycardic effect of Analgesics (Opioid).
SufentanilCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
SulconazoleCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
SulfisoxazoleCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
SuvorexantCNS Depressants may enhance the CNS depressant effect of Suvorexant.
TamoxifenCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
TapentadolMay enhance the CNS depressant effect of CNS Depressants.
Tedizolid PhosphateMAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.
TelaprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
TelithromycinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
TemazepamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TemsirolimusCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
TeniposideCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
TetrabenazineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TetracyclineCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Hydrocodone.
ThalidomideCNS Depressants may enhance the CNS depressant effect of Thalidomide.
ThioridazineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ThiothixeneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TiagabineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TiclopidineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
TicrynafenAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
TipranavirCYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Hydrocodone. Specifically, concentrations of hydromorphone may be decreased.
TizanidineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TolcaponeCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TolvaptanCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
TopiramateCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TorasemideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
TramadolCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TrametinibCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
TranylcypromineMAO Inhibitors may enhance the adverse/toxic effect of Hydrocodone.
TriamtereneAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
TriazolamCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TrichlormethiazideAnalgesics (Opioid) may enhance the adverse/toxic effect of Diuretics.
TrifluoperazineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TrimipramineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
TriprolidineCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
VemurafenibCYP3A4 Inducers (Weak) may decrease the serum concentration of Hydrocodone.
VenlafaxineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
VigabatrinCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
VinblastineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
VincristineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
VinorelbineCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
VoriconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
ZafirlukastCYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.
ZaleplonCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ZiconotideCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ZiprasidoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ZolpidemCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ZonisamideCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ZopicloneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
ZuclopenthixolCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
Food Interactions
  • Avoid alcohol.
  • Take with food.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).

Targets

1. Mu-type opioid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Mu-type opioid receptor P35372 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC: The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9. Pubmed
  3. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. Pubmed
  4. Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80. Pubmed
  5. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. Pubmed
  6. Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL: Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010 Jul 28. Pubmed
  7. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. Epub 2008 Jul 7. Pubmed

2. Delta-type opioid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Delta-type opioid receptor P41143 Details

References:

  1. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. Pubmed
  2. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12